Orzaks İlaç Launches IPO Worth TRY 3.6 Billion

Orzaks İlaç has initiated an initial public offering (IPO) totaling TRY 3.6 billion. With this move, the company aims to enter the capital markets and expand its investor base. The details of the IPO are shaped in line with the company's growth strategy and financial targets. Under the IPO, existing shareholders of Orzaks İlaç will sell a certain portion of their shares. The proceeds are planned to be used for areas such as R&D activities, increasing production capacity, and entering new markets. This process aims to enhance competitiveness in the pharmaceutical sector. The IPO, expected to attract investor interest, is considered a significant transaction in Turkey's capital markets. Orzaks İlaç's position in the sector and growth potential may influence demand for the offering. The company emphasizes its commitment to transparency and corporate governance principles post-IPO. The timing and price range of the IPO will be determined based on market conditions. Detailed information will be shared with the public through the prospectus and other official documents. Investors are advised to closely monitor the process. This is not investment advice.